Home » Thought Leadership » Page 2

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 12 posts
ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Importance of the Overall Survival Endpoint in EU HTA Decision-Making

ISPOR International 2019: CBPartners presented a research poster to describe the importance of the overall survival (OS) endpoint in EU HTA decision-making.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Rising Patient Voice – Changing Value of PRO and QoL Metrics

ISPOR International 2019: CBPartners presented a reseach poster about the changing value of patient-reported outcome (PRO) and quality of life (QoL) metrics.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Importance of Overall Survival as a Clinical Endpoint in FDA vs. EMA Regulatory Approval

ISPOR International 2019: CBPartners presented a poster about the importance of overall survival (OS) data as a clinical endpoint in FDA vs. EMA regulatory approval.

March 5, 2018 | Blog

CAR T-Cell Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome

After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. CBPartners' Cell and Gene Therapy Center of Excellence explores the challenges that CAR-T combination therapies face.